#United States #Sunnyvale #Inflammatix #TriVerity #Infection Management

Inflammatix's TriVerity™ Test Receives NTAP Reimbursement Approval

In a significant leap for host-response diagnostics, Inflammatix has announced that its TriVerity™ Test will be covered by the New Technology Add-On Payment (NTAP) for the fiscal year 2026. This approval from the Centers for Medicare & Medicaid Services (CMS) positions the TriVerity Test as a pioneering tool in emergency medicine, particularly for managing suspected infections and sepsis. Unlike traditional diagnostic methods, the TriVerity Test combines varying insights—specific to bacterial and viral infections—into a singular severity score derived from a simple blood draw, with results available in approximately 30 minutes.

A Revolutionary Approach to Diagnostics

The TriVerity Test incorporates three integrated host-response scores: one for bacterial infection, another for viral infection, and a vital severity score. This approach significantly enhances clinicians' ability to assess a patient's condition comprehensively and makes it easier to devise a suitable treatment strategy based on the urgency needed.

Dr. Tim Sweeney, CEO and co-founder of Inflammatix, explains the critical implications of the severity score: "This score is the first of its kind that translates host-response biomarkers into a quantitative risk assessment, capable of predicting clinical deterioration. Such an innovation allows for early identification of high-risk patients while facilitating more confident discharge decisions for low-acuity cases."

The NTAP approval means that hospitals can receive additional payments beyond the standard Diagnosis-Related Group (DRG) rate for eligible inpatient cases utilizing the TriVerity Test. This financial support opens doors for wider adoption of advanced diagnostic technologies that promise to reshape emergency care.

Transforming Emergency Care Decision-Making

One of the hallmark features of the TriVerity Test is its ability to combine the infection type with the urgency of care needed. This dual information acts as a decision-making tool that supports healthcare providers in understanding not just the nature of the infection but also the immediate actions required to improve patient outcomes. For instance, when clinicians can pinpoint both the infection type and assess how critical a patient's condition is, they are better equipped to make faster, more informed decisions.

With a clear pathway established for adopting these cutting-edge diagnostic methodologies, Inflammatix is setting a new paradigm in the way acute infections and sepsis are diagnosed and managed. As traditional methods fall short of providing the real-time data necessary for life-saving treatments, innovations like TriVerity are quickly becoming indispensable components of patient care protocols.

About Inflammatix

Founded with the mission of transforming diagnostic procedures, Inflammatix is recognized as a leader in utilizing host-response diagnostics. Their flagship TriVerity Test not only aims to enhance clinical decision-making but also strives to maximize the effective use of healthcare resources. The company has earned backing from numerous prominent investors, reinforcing its potential impact on the healthcare landscape.

As Inflammatix continues to innovate in the field of diagnostics, healthcare providers are hopeful that such advancements will significantly improve patient care, particularly in emergency settings. By understanding both the acute effects of infections and their physiological impacts on immune responses, clinicians can provide more timely interventions that are essential in critical care environments.

To discover more about Inflammatix and their groundbreaking products, visit their website or follow them on social media channels.